Middle East Respiratory Syndrome (MERS) - Pipeline Review, H2 2016 - Therapeutics Assessment By Drug Target, MoA, RoA & Molecule Type - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Middle East Respiratory Syndrome (MERS) - Pipeline Review, H2 2016" report to their offering.

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

This report provides comprehensive information on the therapeutic development for Middle East Respiratory Syndrome (MERS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Middle East Respiratory Syndrome (MERS) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned:

• Atriva Therapeutics GmbH
• Autoimmune Technologies LLC
• Humabs BioMed SA
• Inovio Pharmaceuticals Inc
• Nanotherapeutics Inc
• Novavax Inc
• Phelix Therapeutics LLC
• Planet Biotechnology Inc
• Regeneron Pharmaceuticals Inc
• Romark Laboratories LC
  

Key Topics Covered:

1. Introduction
2. Middle East Respiratory Syndrome (MERS) Overview
3. Therapeutics Development
4. Pipeline Products for Middle East Respiratory Syndrome (MERS) - Overview
5. Pipeline Products for Middle East Respiratory Syndrome (MERS) - Comparative Analysis
6. Middle East Respiratory Syndrome (MERS) - Therapeutics under Development by Companies
7. Middle East Respiratory Syndrome (MERS) - Therapeutics under Investigation by Universities/Institutes
8. Middle East Respiratory Syndrome (MERS) - Pipeline Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Middle East Respiratory Syndrome (MERS) - Products under Development by Companies
13. Middle East Respiratory Syndrome (MERS) - Products under Investigation by Universities/Institutes
14. Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development

For more information about this report visit http://www.researchandmarkets.com/research/5d8bp4/middle_east